China Biologic Products Holdings Inc
China Biologic Products — Investor Presentation (May 2008)
8 slides from China Biologic Products's investor presentation, May 19, 2008
Slide 1: China Biologic Products - Investment Highlights
a China Biologic Products CBPO.OB Price (05/13/08): $2.95 '52-Week Range: §2.70-§5.85 Market Value: $632M Shares Outstanding - Diluted (as of 03/3108): 20M Revenues (FYO7): $32.4M Net income (FY07): $82M EPS-Diluted (FY07}: $0.37 PiE-Diluted (FYO7); 0X Fiscal Year End December 34 COMPANY DESCRIPTION
Slide 2: Plasma-Based Product Industry in China
PLASMA-BASED PRODUCT INDUSTRY IN CHINA Favorable Macroeconomic Conditions - Due to sustained improvement in China's economy, the pharmaceutical market in China is expected to be the world's fifth largest Prarmgoeulal (RNB bition market by 2010 and the largest by RMB bilen) 1725 cen 2050 according to
Slide 3: Types of Plasma Products Used / Corporate Overview
Types of Plasma Products Used Number of Plasma Various types of Region Products Human Albumin \mmunogiobulin Clotting Factors China 48 15% 20% 5% Developed counties 40.20 25% 25% 50% Consolidating Industry - A reliable supply of clean and qualified blood is a key success factor for companies in this
Slide 4: Product Portfolio
Product Portfolio - Sales of Human Albumin products contributed approximately 63.4% of total revenues for 2007. Human Albumin is principally used to increase blood volume while immunoglobulin is used for certain diseases prevention and cure. Shandong Taibang’s Human Albumin and immunoglobulin produc
Slide 5: Stringent Quality Control and Research and Development
Stringent Quality Control — The Company was awarded an Advanced High-tech Enterprise Certification by the Department of Science and Technology of Shandong Province in 2005 and by the Ministry of Science and Technology of the PRC in 2006. All of China Biologics products are covered by product liabili
Slide 6: Lead Industry Consolidation / Develop New, Higher Margin Products
Lead Industry Consolidation - There are 34 approved plasma-based biopharmaceutical manufacturers inthe market. Half of them are not competitive due to lack of plasma supply, have obsolete production facilities or have smaller product portfolios. Regulatory authorities have advanced plans to reform t
Slide 7: Management Team
Bachelor degree in Accounting from the University of Kent in the UK. He is also a fellow member of the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants, Tung Lam (CEO of Shangdong Taibang) has been the Chief Executive Officer of our operating
Slide 8: Selected Financial Data
g_SELECTED FINANCIAL DATA China Biologic Products, Inc., Three Months Ended March 31 __Year ended December 31 Consolidated Income Statement (US$) Uae zoo once Revenues 7,849,007 32,398,669 22,230,570 Cost of revenues 1,948,898 9,945,921 9,601,605 Gross Profit 5,900,109 22,452,748 42/628,965 Operatin
China Biologic Products — Investor Presentation (May 2008) on 6ix